Evidence map›Paper›PMID 34566620›Full record

ArticleFrontiers in aging neuroscience2021

Age at Disease Onset Associates With Oxidative Stress, Neuroinflammation, and Impaired Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis.

Mario Stampanoni Bassi, Luana Gilio, Ennio Iezzi, Alessandro Moscatelli, Tatjana Pekmezovic, Jelena Drulovic, Roberto Furlan, Annamaria Finardi, Georgia Mandolesi, Alessandra Musella and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. CNS Ageing in Health and Neurodegenerative Disorders.Journal of clinical medicine · 2023
    Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Mario Stampanoni BassiUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Luana GilioUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Ennio IezziUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Alessandro MoscatelliDepartment of Systems Medicine, Tor Vergata University, Rome, Italy.
Tatjana PekmezovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Jelena DrulovicClinic of Neurology, Clinical Center of Serbia, Belgrade, Serbia.
Roberto FurlanClinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Annamaria FinardiClinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Georgia MandolesiSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, Rome, Italy.
Alessandra MusellaSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, Rome, Italy.
Giovanni GalifiUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Roberta FantozziUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Paolo BellantonioUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Marianna StortoUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Diego CentonzeUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Fabio ButtariUnit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy.
Istituto Neurologico Mediterraneo · ITSan Raffaele University of Rome · ITCentar za Promociju Nauke · RSIRCCS Ospedale San Raffaele · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age at onset is the main risk factor for disease progression in patients with relapsing-remitting multiple sclerosis (RR-MS). In this cross-sectional study, we explored whether older age is associated with specific disease features involved in the progression independent of relapse activity (PIRA). In 266 patients with RR-MS, the associations between age at onset, clinical characteristics, cerebrospinal fluid (CSF) levels of lactate, and that of several inflammatory molecules were analyzed. The long-term potentiation (LTP)-like plasticity was studied using transcranial magnetic stimulation (TMS). Older age was associated with a reduced prevalence of both clinical and radiological focal inflammatory disease activity. Older patients showed also increased CSF levels of lactate and that of the pro-inflammatory molecules monocyte chemoattractant protein 1 (MCP-1)/CCL2, macrophage inflammatory protein 1-alpha (MIP-1α)/CCL3, and interleukin (IL)-8. Finally, TMS evidenced a negative correlation between age and LTP-like plasticity. In newly diagnosed RR-MS, older age at onset is associated with reduced acute disease activity, increased oxidative stress, enhanced central inflammation, and altered synaptic plasticity. Independently of their age, patients with multiple sclerosis (MS) showing similar clinical, immunological, and neurophysiological characteristics may represent ideal candidates for early treatments effective against PIRA.

Indexed as

agingneuroinflammationoxidative stressprogression of disability independent of disease activityrelapsing remitting multiple sclerosissynaptic plasticity

Identifiers

PMID34566620
PMCPMC8461180
OpenAlexW3199905392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.